Laboratory of Genetics (BIOZ)

bioz.gr

The Laboratory of Genetics, Comparative and Evolutionary Biology (BIOZ) was founded by the Presidential Decree 1971/10-9-2009. BIOZ evolved from a multi-disciplinary research group originally established to concentrate on research of animal genetics, to elucidate the functional and ecological benefits of genetic polymorphism at the organism and population level and to use the fruits of the research for the development of possible applications.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

NOVALIQ SUBMITS NEW DRUG APPLICATION SEEKING APPROVAL FOR FIRST-OF-A-KIND DRY EYE DISEASE TREATMENT CYCLASOL®

Novaliq GmbH | August 10, 2022

news image

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announced the submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval for CyclASol® a proposed novel treatment for the signs and symptoms of dry eye disease. CyclASol® has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improveme...

Read More

Industry Outlook

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

news image

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More

Medical

WUXI ATU AND WUGEN ANNOUNCE MANUFACTURING PARTNERSHIP TO EXPEDITE THE DELIVERY OF NOVEL CELL CANCER IMMUNOTHERAPIES

Wugen | June 16, 2022

news image

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...

Read More

Cell and Gene Therapy

GINKGO BIOWORKS LAUNCHES CELL DEVELOPMENT KIT SERVICE FOR STANDARDIZED, LOW-COST ENTRY TO ITS CELL PROGRAMMING PLATFORM

ginkgo biowork | November 11, 2021

news image

ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered ...

Read More
news image

Industrial Impact

NOVALIQ SUBMITS NEW DRUG APPLICATION SEEKING APPROVAL FOR FIRST-OF-A-KIND DRY EYE DISEASE TREATMENT CYCLASOL®

Novaliq GmbH | August 10, 2022

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announced the submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval for CyclASol® a proposed novel treatment for the signs and symptoms of dry eye disease. CyclASol® has demonstrated in two pivotal studies fast onset of therapeutic effect in the indication, clinical meaningful improveme...

Read More
news image

Industry Outlook

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More
news image

Medical

WUXI ATU AND WUGEN ANNOUNCE MANUFACTURING PARTNERSHIP TO EXPEDITE THE DELIVERY OF NOVEL CELL CANCER IMMUNOTHERAPIES

Wugen | June 16, 2022

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...

Read More
news image

Cell and Gene Therapy

GINKGO BIOWORKS LAUNCHES CELL DEVELOPMENT KIT SERVICE FOR STANDARDIZED, LOW-COST ENTRY TO ITS CELL PROGRAMMING PLATFORM

ginkgo biowork | November 11, 2021

ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered ...

Read More